A carregar...
Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
BACKGROUND: Lanreotide and octreotide acetate suspension for injectable (LAR) are both recommended for clinical use in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. However, each agent possesses unique attributes in terms of their drug-delivery characteri...
Na minha lista:
| Publicado no: | J Oncol Pharm Pract |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6643159/ https://ncbi.nlm.nih.gov/pubmed/30924737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155219839458 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|